Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug in Primary Membranous Nephropathy
NCT07096843Phase 2Recruiting
- Sponsor
- Climb Bio
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of budoprutug in primary membranous nephropathy (PMN), sponsored by Climb Bio. Started Aug 2025; status: recruiting.
02
Drugs
budoprutug
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07096843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096843.